Enter Imprimis, who, through its spinoff Eton Pharmaceuticals, just announced it will be launching a competitor to Acthar, while enlisting the former CEO of Questcor to join its Board of Directors and advise on its’ launch of an Acthar competitor.
Eton plans on charging 40% less for its product than Mallinckrodt’s price.
When Imprimis did this to Mylan and the EpiPen, Mylan immediately created a generic version at half the price of the branded EpiPen. Imprimis executed a similar strategy with Turing Pharma, through the launch of a generic costing 1/750th of Turing’s price, immediately forcing Turing to reduce its drug’s price.
Lower priced alternatives to Acthar will enable patients to be treated with a product that has a direct filed safety profile with the FDA, and will create a disincentive for bad medicine to be practiced for the sake of greed.
More importantly, by being able to focus on people who can really benefit by Acthar and not be forced by the burden of a multi billion debt load, Eton will be able to penetrate and dominate the only market that Acthar Gel has a place in and not further hurt its patient base.
The most expensive drug on the Medicare dashboard is:
- Over Prescribed
- Inferior to Competition
- … and now Dangerous
The FDA has told you, their former employees have told you, and we now wait for the Department of Justice.
It is time for Congress or Express Scripts to act responsibly and stop this billion dollar charade before more people are hurt.